Human In Vivo Therapeutics Field Sublicenses. Subject to the rights of the Primary Sublicensors and their respective owners under Section 10.4, Cellscript, mRNA RiboTherapeutics and Company agree that, from the Effective Date until [***], mRNA RiboTherapeutics and Cellscript will not grant and will ensure that other Primary Sublicensors will not grant Human In Vivo Therapeutics Field Sublicenses[***].
Appears in 3 contracts
Samples: Patent Sublicense Agreement (Moderna, Inc.), Patent Sublicense Agreement (Moderna, Inc.), Patent Sublicense Agreement (Moderna, Inc.)
Human In Vivo Therapeutics Field Sublicenses. Subject to the rights of the Primary Sublicensors and their respective owners under Section 10.4, Cellscript, mRNA RiboTherapeutics and Company agree that, from the Effective Date until [***], mRNA RiboTherapeutics and Cellscript will not grant and will ensure that other Primary Sublicensors will not grant Human In Vivo Therapeutics Field Sublicenses, including this Sublicense, to [***].
Appears in 3 contracts
Samples: Patent Sublicense Agreement, Patent Sublicense Agreement (BioNTech SE), Patent Sublicense Agreement (BioNTech SE)
Human In Vivo Therapeutics Field Sublicenses. Subject to the rights of the Primary Sublicensors and their respective owners under Section 10.4, Cellscript, mRNA RiboTherapeutics and Company agree that, from the Effective Date until [***], mRNA RiboTherapeutics and Cellscript will not grant and will ensure that other Primary Sublicensors will not grant Human In Vivo Therapeutics Field Sublicenses, including this Sublicense, to [***].
Appears in 2 contracts
Samples: Patent Sublicense Agreement (BioNTech SE), Patent Sublicense Agreement (BioNTech SE)
